vTv Therapeutics Inc
VTVT29.020USD
-1.990-6.42%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
114.28MCap. mercado
PérdidaP/E TTM
Más Datos de vTv Therapeutics Inc Compañía
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Información de vTv Therapeutics Inc
Símbolo de cotizaciónVTVT
Nombre de la empresavTv Therapeutics Inc
Fecha de salida a bolsaJul 30, 2015
Director ejecutivoSekhri (Paul Jai)
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección3980 Premier Dr
CiudadHIGH POINT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27265
Teléfono13368410300
Sitio Webhttps://vtvtherapeutics.com/
Símbolo de cotizaciónVTVT
Fecha de salida a bolsaJul 30, 2015
Director ejecutivoSekhri (Paul Jai)
Ejecutivos de vTv Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-24062.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
+2146.00%
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
+1833.00%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
-2251.00%
Mr. Daniel (Dan) Spiegelman
Mr. Daniel (Dan) Spiegelman
Director
Director
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-24062.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
+2146.00%
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
+1833.00%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Desglose de ingresos
FY2023
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: vie., 6 de feb
Actualizado: vie., 6 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
MacAndrews & Forbes Holdings, Inc.
23.18%
Samsara BioCapital, LLC
7.58%
Trails Edge Capital Partners LP
5.87%
Fidelity Management & Research Company LLC
4.90%
Invus Public Equities Advisors, LLC
4.14%
Otro
54.33%
Accionistas
Accionistas
Proporción
MacAndrews & Forbes Holdings, Inc.
23.18%
Samsara BioCapital, LLC
7.58%
Trails Edge Capital Partners LP
5.87%
Fidelity Management & Research Company LLC
4.90%
Invus Public Equities Advisors, LLC
4.14%
Otro
54.33%
Tipos de accionistas
Accionistas
Proporción
Holding Company
23.18%
Investment Advisor
17.37%
Venture Capital
7.58%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
0.75%
Individual Investor
0.42%
Otro
46.35%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
44
1.18M
30.04%
+255.03K
2025Q3
47
1.15M
29.13%
+562.26K
2025Q2
54
1.51M
57.66%
-17.51K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
MacAndrews & Forbes Holdings, Inc.
912.98K
23.18%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
298.50K
7.58%
-75.97K
-20.29%
Dec 08, 2025
Trails Edge Capital Partners LP
231.00K
5.87%
+231.00K
--
Aug 29, 2025
Fidelity Management & Research Company LLC
192.89K
4.9%
+14.69K
+8.24%
Sep 30, 2025
Invus Public Equities Advisors, LLC
163.00K
4.14%
--
--
Sep 30, 2025
Baker Bros. Advisors LP
148.31K
3.77%
+51.00K
+52.41%
Sep 30, 2025
The Vanguard Group, Inc.
46.99K
1.19%
+3.81K
+8.84%
Sep 30, 2025
Geode Capital Management, L.L.C.
15.30K
0.39%
+2.43K
+18.90%
Sep 30, 2025
Northern Trust Investments, Inc.
14.07K
0.36%
-1.22K
-7.95%
Sep 30, 2025
Millennium Management LLC
12.94K
0.33%
-2.11K
-14.01%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
